Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mebendazole in recurrent pediatric brain tumors
NCT02644291Phase 1Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- May 2016
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mebendazole in medulloblastoma and high-grade glioma (HGG), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Adverse events at 2 years. Started May 2016; status: completed.
02
Drugs
mebendazole
03
Conditions
medulloblastomahigh-grade glioma (HGG)
Beyond the preview
Go deeper on NCT02644291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02644291.